Sodium Glycerophosphate

Summary

Sodium Glycerophosphate (CHEMBL6067979) is an approved unknown (ATC B05XA14).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• ATC class: B05XA14
• Clinical trials: 1

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL6067979
Name	Sodium Glycerophosphate
Type	Unknown
Max phase	4
ATC	B05XA14

Also known as: Sodium glycerophosphate, Sodium glycerophosphate hydrate, SODIUM GLYCEROPHOSPHATE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06754670	Not specified	RECRUITING	Effect of Hypophosphatemia on Neuro-excursion Efficiency During Mechanical Ventilator Weaning

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).